LIVIVO - Suchergebnisse -

Suchergebnis

Treffer 1 - 10 von insgesamt 41

Suchoptionen

Buch ; Online ; Dissertation / Habilitation: Etablierung eines Verfahrens zur Kryokonservierung einzelner Spermatozoen

Koch, Cornelia [Verfasser]

2016

Verfasserangabe	Cornelia Koch
Schlagwörter	Medizin, Gesundheit ; Medicine, Health
Thema/Rubrik (Code)	sg610
Sprache	Deutsch
Verlag	Universitäts- und Landesbibliothek Bonn
Erscheinungsort	Bonn
Dokumenttyp	Buch ; Online ; Dissertation / Habilitation
Datenquelle	Digitale Dissertationen im Internet

Volltext online

Volltext online

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Buch ; Online ; Dissertation / Habilitation: Annahmeverzug des Arbeitgebers während des Kündigungsschutzprozesses

Koch, Cornelia

Möglichkeiten zur Risikominimierung

2007

Verfasserangabe	vorgelegt von Cornelia Koch
Sprache	Englisch
Umfang	Online-Ressource (PDF-Datei: XXVI, 168 S., 1.750 KB)
Verlag	Universitätsbibliothek
Erscheinungsort	Konstanz
Dokumenttyp	Buch ; Online ; Dissertation / Habilitation
Dissertation / Habilitation	Univ. , Diss.--Konstanz, 2007
Datenquelle	Ehemaliges Sondersammelgebiet Küsten- und Hochseefischerei

Volltext online

Volltext online

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel ; Online: Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry.

Maggioni, Aldo P / Clark, Andrew L / Barrios, Vivencio / Damy, Thibaud / Drozdz, Jaroslaw / Fonseca, Candida / Lund, Lars H / Kalus, Stefanie / Ferber, Philippe C / Hussain, Rizwan I / Koch, Cornelia / Zeymer, Uwe

ESC heart failure

2022

Abstract: Aims: ARIADNE aimed to assess the association between effects of sacubitril/valsartan and no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical outcomes (cause-specific mortality and hospitalizations) in ... ...

Abstract	Aims: ARIADNE aimed to assess the association between effects of sacubitril/valsartan and no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical outcomes (cause-specific mortality and hospitalizations) in outpatients with heart failure (HF) with reduced ejection fraction (HFrEF). Methods: ARIADNE was a prospective European registry of 9069 patients with HFrEF treated by office-based cardiologists or selected primary care physicians. Of the 8787 eligible for analysis, 4173 patients were on conventional HF treatment (non-S/V group), whereas 4614 patients were either on sacubitril/valsartan treatment at enrolment or started sacubitril/valsartan within 1 month of enrolment (S/V group). We also generated a restricted analysis set (rS/V) including only those 2108 patients who started sacubitril/valsartan treatment within the month prior to or after enrolment. Results: At the baseline, average age of patients enrolled in the study was 68 years, and 23.9% (2099/8787) were female. At the baseline, the proportions of patients with New York Heart Association (NYHA) Class III symptoms were 30.9 (1288/4173), 42.8 (1974/4614), and 48.2% (1015/2108), in non-S/V, S/V, and rS/V groups, respectively. After 12 months of treatment, the proportion of patients with NYHA Class III at baseline who improved to Class II was 32.0% (290/907) in the non-S/V group vs. 46.3% (648/1399) in S/V group and 48.7% (349/717) in rS/V group. The overall mortality rate was 5.0 per 100 patient-years. Rates of HF hospitalizations were high (20.9, 20.3, and 21.2 per 100 patient-years in the non-S/V, S/V, and rS/V groups, respectively). Emergency room visits without hospitalization occurred in 3.9, 3.2, and 3.9% of patients in the non-S/V, S/V, and rS/V groups, respectively. Conclusions: This large HFrEF European registry provides a contemporary outcome profile of outpatients with HFrEF treated with or without sacubitril/valsartan. In a real-world setting, sacubitril/valsartan was associated with an improvement of symptoms in patients with HFrEF compared with the conventional HFrEF treatment.
Sprache	Englisch
Erscheinungsdatum	2022-09-15
Erscheinungsland	England
Dokumenttyp	Journal Article
ZDB-ID	2814355-3
ISSN	2055-5822 ; 2055-5822
ISSN (online)	2055-5822
ISSN	2055-5822
DOI	10.1002/ehf2.14014
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Details ▾
- Kostenpflichtig bestellen

Artikel ; Online: Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.

Lund, Lars H / Zeymer, Uwe / Clark, Andrew L / Barrios, Vivencio / Damy, Thibaud / Drożdż, Jaroslaw / Fonseca, Candida / Kalus, Stefanie / Ferber, Philippe C / Koch, Cornelia / Maggioni, Aldo P

International journal of cardiology

2022 Band 370, Seite(n) 279–286

Abstract: Aims: We tested the hypothesis that initiation versus non-initiation of sacubitril/valsartan is associated with a more favorable subsequent change in left ventricular ejection fraction (LVEF) in a real-world setting.: Methods: A prospective, non- ... ...

Abstract	Aims: We tested the hypothesis that initiation versus non-initiation of sacubitril/valsartan is associated with a more favorable subsequent change in left ventricular ejection fraction (LVEF) in a real-world setting. Methods: A prospective, non-randomized, double-arm, open-label, cohort study had been conducted across 687 centers in 17 European countries enrolling HFrEF patients aged ≥18 years with symptoms of HF (New York Heart Association [NYHA] II-IV) and "reduced LVEF". For the current analysis, 2602 patients with LVEF measured at baseline and follow-up were chosen, of which 860 (33%, mean age 67 years, 26% women) were started on sacubitril/valsartan at baseline and 1742 (67%, 68 years, 23% women) were not. Patients started on sacubitril/valsartan had higher NYHA class and lower LVEF. Results: LVEF increased from mean 32.7% to 38.1% in the sacubitril/valsartan group versus from 35.9% to 38.7% in the non-sacubitril/valsartan group (mean difference in increase 2.6%, p < 0.001). LVEF increased from baseline in 64% versus 53% of patients and increased by ≥5% (absolute %) in 50% versus 35% of patients in the sacubitril/valsartan versus non-sacubitril/valsartan groups, respectively. In the overall cohort, initiation of sacubitril/valsartan was independently associated with any increase in LVEF (adjusted odds ratio [OR] 1.49 [1.26-1.75]) and with increase by ≥5% (OR 1.65 [1.39-1.95]). Conclusion: Initiating versus not initiating sacubitril/valsartan was independently associated with a greater subsequent increase in LVEF in this real-world setting. Reverse cardiac remodeling may be one mechanism of benefit of sacubitril/valsartan.
Sprache	Englisch
Erscheinungsdatum	2022-10-07
Erscheinungsland	Netherlands
Dokumenttyp	Journal Article
ZDB-ID	779519-1
ISSN	1874-1754 ; 0167-5273
ISSN (online)	1874-1754
ISSN	0167-5273
DOI	10.1016/j.ijcard.2022.10.012
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 1673: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.

Forst, Thomas / Koch, Cornelia / Dworak, Markus

Current medical research and opinion

2015 Band 31, Heft 6, Seite(n) 1079–1084

Abstract: Objective: There is limited evidence to guide the selection of second-line anti-hyperglycemic agents in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled with sulfonylurea monotherapy and are intolerant to metformin. We ... ...

Abstract	Objective: There is limited evidence to guide the selection of second-line anti-hyperglycemic agents in patients with type 2 diabetes mellitus (T2DM) who are inadequately controlled with sulfonylurea monotherapy and are intolerant to metformin. We compared the efficacy and safety of vildagliptin 50 mg qd and Neutral Protamine Hagedorn (NPH) insulin qd in such patients. Methods: This was a 24 week, multicenter, randomized, open-label study. The co-primary endpoints were (i) proportion of patients achieving HbA1c <7.0% without any confirmed hypoglycemic events (HEs) or weight gain ≥3% (composite endpoint); (ii) rate of confirmed HEs. Treatment satisfaction was assessed using the TSQM-9 questionnaire at study end. Results: A total of 162 patients were randomly assigned to vildagliptin (n = 83) and NPH insulin (n = 79). Similar proportion of patients achieved the composite endpoint in vildagliptin versus NPH insulin group (35.4% versus 34.2%; OR 0.985; 95% CI 0.507, 1.915; p = 0.96). After 24 weeks, 48.8% of patients in the vildagliptin group and 60.8% in the NPH insulin group achieved HbA1c <7.0%; 13.4% in the vildagliptin group and 29.1% in the insulin group had at least one confirmed HE; while 11.0% in the vildagliptin group and 22.8% in the insulin group experienced weight gain. The rate of confirmed HEs was significantly lower in patients receiving vildagliptin versus NPH insulin (1.3 versus 5.1 events per year). The TSQM-9 score for 'convenience' at week 24 increased significantly more with vildagliptin than with NPH insulin. Conclusions: Addition of vildagliptin and NPH insulin resulted in a similar number of patients reaching HbA1c target without HEs or weight gain in T2DM patients inadequately controlled with sulfonylurea. The addition of vildagliptin to sulfonylurea could be considered as a treatment option prior to intensification with insulin, with the advantages of a lower HE rate and greater patient convenience. Study results are limited by a higher drop-out rate in the vildagliptin arm.
Mesh-Begriff(e)	Adamantane/analogs & derivatives ; Adamantane/therapeutic use ; Adult ; Diabetes Mellitus, Type 2/drug therapy ; Female ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin, Isophane/therapeutic use ; Male ; Middle Aged ; Nitriles/therapeutic use ; Pyrrolidines/therapeutic use ; Sulfonylurea Compounds/therapeutic use ; Weight Gain/drug effects
Chemische Substanzen	Hypoglycemic Agents ; Nitriles ; Pyrrolidines ; Sulfonylurea Compounds ; Insulin, Isophane (53027-39-7) ; vildagliptin (I6B4B2U96P) ; Adamantane (PJY633525U)
Sprache	Englisch
Erscheinungsdatum	2015-06
Erscheinungsland	England
Dokumenttyp	Comparative Study ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	80296-7
ISSN	1473-4877 ; 0300-7995
ISSN (online)	1473-4877
ISSN	0300-7995
DOI	10.1185/03007995.2015.1039936
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Volltext online

Zugriff für angemeldete ZB MED Nutzerinnen und Nutzer

Zusatzmaterialien

Verfügbar in ZB MED Köln/Königswinter

Zs.A 955: Hefte anzeigen

Standort:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Über subito bestellen

Details ▾

Artikel ; Online: Individualised treatment targets in patients with type-2 diabetes and hypertension.

Schmieder, Roland E / Tschöpe, Diethelm / Koch, Cornelia / Ouarrak, Taoufik / Gitt, Anselm K

Cardiovascular diabetology

2018 Band 17, Heft 1, Seite(n) 18

Abstract: Aim: Patients with type-2 diabetes mellitus (T2DM) are at high risk of cardiovascular events, accentuated in the presence of hypertension. At present, it is unclear to what extent the guidelines for the management of T2DM, advocating reduction in HbA1c ... ...

Abstract	Aim: Patients with type-2 diabetes mellitus (T2DM) are at high risk of cardiovascular events, accentuated in the presence of hypertension. At present, it is unclear to what extent the guidelines for the management of T2DM, advocating reduction in HbA1c levels to below target levels, are being adhered to in clinical practice. Methods: DIALOGUE was a prospective, observational, non-interventional registry performed across multiple centres in Germany. Patients aged 18 years or older who had T2DM and hypertension for whom the treating physician considered blood glucose lowering medication as inadequate and/or not safe/tolerable and chose to add a further oral drug or switch drug treatment were included. Patients were assigned a treatment target HbA1c value (≤ 6.5% [strict]; > 6.5 to ≤ 7.0% [intermediate]; > 7.0 to ≤ 7.5% [lenient]). Results: 8568 patients with T2DM and hypertension were enrolled. 6691 (78.1%) had 12-month follow-up. Patients who were assigned a strict HbA1c treatment target (n = 2644) were younger, had shorter diabetes duration, and less comorbidity in comparison to those with intermediate (n = 2912) or lenient targets (n = 1135). Only 53.1% of patients achieved their HbA1c treatment target (46.2% [strict], 56.8% [intermediate], 59.4% [lenient]). There was little sign of treatment intensification for patients that had not achieved their HbA1c target. Conclusions: Achievement of treatment targets was poor, leaving many patients with sub-optimal blood glucose levels. The apparent reluctance of physicians to intensify antidiabetic drug therapy is alarming, especially considering the evidence pointing to an association of hyperglycaemia and microvascular complications in patients with T2DM.
Mesh-Begriff(e)	Aged ; Biomarkers/blood ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Blood Pressure ; Clinical Decision-Making ; Comorbidity ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Drug Substitution ; Drug Therapy, Combination ; Female ; Germany/epidemiology ; Glycated Hemoglobin A/metabolism ; Guideline Adherence ; Humans ; Hypertension/diagnosis ; Hypertension/epidemiology ; Hypertension/physiopathology ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/adverse effects ; Male ; Middle Aged ; Practice Guidelines as Topic ; Practice Patterns, Physicians' ; Prospective Studies ; Registries ; Risk Factors ; Time Factors ; Treatment Outcome
Chemische Substanzen	Biomarkers ; Blood Glucose ; Glycated Hemoglobin A ; Hypoglycemic Agents ; hemoglobin A1c protein, human
Sprache	Englisch
Erscheinungsdatum	2018-01-22
Erscheinungsland	England
Dokumenttyp	Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
ISSN	1475-2840
ISSN (online)	1475-2840
DOI	10.1186/s12933-018-0661-8
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾
- Kostenpflichtig bestellen

Buch ; Online ; Dissertation / Habilitation: Annahmeverzug des Arbeitgebers während des Kündigungsschutzprozesses

Koch, Cornelia [Verfasser]

Möglichkeiten zur Risikominimierung

2007

Verfasserangabe	vorgelegt von Cornelia Koch
Schlagwörter	Recht ; Law
Thema/Rubrik (Code)	sg340
Sprache	Englisch
Dokumenttyp	Buch ; Online ; Dissertation / Habilitation
Datenquelle	Digitale Dissertationen im Internet

Volltext online

Volltext online

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Artikel ; Online: Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.

Zeymer, Uwe / Clark, Andrew L / Barrios, Vivencio / Damy, Thibaud / Drożdż, Jaroslaw / Fonseca, Candida / Lund, Lars H / Kalus, Stefanie / Ferber, Philippe C / Hussain, Rizwan I / Koch, Cornelia / Maggioni, Aldo P

European heart journal. Quality of care & clinical outcomes

2021 Band 8, Heft 4, Seite(n) 469–477

Abstract: Aims: To compare baseline characteristics of patients with heart failure with reduced ejection fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on conventional heart failure (HF)-treatment in a European out-patient ... ...

Abstract	Aims: To compare baseline characteristics of patients with heart failure with reduced ejection fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on conventional heart failure (HF)-treatment in a European out-patient setting. Methods and results: Between July 2016 and July 2019, ARIADNE enrolled 8787 outpatients aged ≥18 years with HFrEF from 17 European countries. Choice of therapy was solely at the investigators' discretion. In total, 4173 patients were on conventional HF-treatment (non-S/V group), while 4614 patients were on sacubitril/valsartan either at enrolment or started sacubitril/valsartan within 1 month of enrolment (S/V group). Of these, 2108 patients started sacubitril/valsartan treatment ±1 month around enrolment [restricted S/V (rS/V) group]. The average age of the patients was 68 years. Patients on S/V were more likely to have New York Heart Association (NYHA) class III or IV symptoms (50.3%, 44.6%, 32.1% in rS/V, S/V, and non-S/V, respectively) and had lower left ventricular ejection fraction (LVEF; 32.3%, 32.7%, and 35.4% in rS/V, S/V, and non-S/V, respectively; P < 0.0001). The most frequently received HF treatments were angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB; ∼84% in non-S/V), followed by β-blockers (∼80%) and mineralocorticoid receptor antagonists (MRAs; 53%). The use of triple HF therapy (ACEI/ARB/angiotensin receptor neprilysin inhibitor with β-blockers and MRA) was higher in the S/V groups than non-S/V group (48.2%, 48.2%, and 40.2% in rS/V, S/V, and non-S/V, respectively). Conclusion: In this large multinational HFrEF registry, patients receiving sacubitril/valsartan tended to be younger with lower LVEF and higher NYHA class. Fewer than half of the patients received triple HF therapy.
Mesh-Begriff(e)	Adolescent ; Adult ; Aged ; Aminobutyrates/therapeutic use ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors ; Biphenyl Compounds ; Heart Failure/drug therapy ; Heart Failure/epidemiology ; Humans ; Registries ; Stroke Volume ; Tetrazoles/therapeutic use ; Treatment Outcome ; Valsartan ; Ventricular Dysfunction, Left ; Ventricular Function, Left
Chemische Substanzen	Aminobutyrates ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Biphenyl Compounds ; Tetrazoles ; sacubitril (17ERJ0MKGI) ; Valsartan (80M03YXJ7I)
Sprache	Englisch
Erscheinungsdatum	2021-03-15
Erscheinungsland	England
Dokumenttyp	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2823451-0
ISSN	2058-1742 ; 2058-5225
ISSN (online)	2058-1742
ISSN	2058-5225
DOI	10.1093/ehjqcco/qcab019
Datenquelle	MEDical Literature Analysis and Retrieval System OnLINE

Zusatzmaterialien

Über subito bestellen

Details ▾
- Kostenpflichtig bestellen

Buch ; Dissertation / Habilitation: Untersuchungen zur prognostischen Aussage der Serumproteinfraktionen erkrankter junger Kälber

Koch, Cornelia Christina

2005

Verfasserangabe	von Cornelia Christina Koch
Sprache	Deutsch
Umfang	101 S, graph. Darst, 21 cm
Dokumenttyp	Buch ; Dissertation / Habilitation
Dissertation / Habilitation	Univ., Diss.--München, 2005
Anmerkung	Zusfassung in dt. und engl. Sprache
Datenquelle	Friedrich Loeffler-Institut, Bundesforschungsinstitut für Tiergesundheit

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾

Buch ; Dissertation / Habilitation: Untersuchungen zur prognostischen Aussage der Serumproteinfraktionen erkrankter junger Kälber

Koch, Cornelia Christina

2005

Verfasserangabe	von Cornelia Christina Koch
Sprache	Deutsch
Umfang	101 S, graph. Darst, 21 cm
Dokumenttyp	Buch ; Dissertation / Habilitation
Dissertation / Habilitation	Univ., Diss.--München, 2005
Anmerkung	Zusfassung in dt. und engl. Sprache
Datenquelle	Ehemaliges Sondersammelgebiet Küsten- und Hochseefischerei

Zusatzmaterialien

Fernleihe an ZB MED

Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Details ▾

Zum Seitenanfang

Ihre letzten Suchen

Volltext online

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Volltext online

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Volltext online

Zusatzmaterialien

Kategorien

Verfügbar in ZB MED Köln/Königswinter

Über subito bestellen

Zusatzmaterialien

Kategorien

Über subito bestellen

Fernleihe an ZB MED

Volltext online

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Über subito bestellen

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED

Zusatzmaterialien

Kategorien

Fernleihe an ZB MED